A Comparative Study of Inhaled Nitric Oxide and an Intravenously Administered Nitric Oxide Donor in Acute Pulmonary Hypertension.

Anna Stene-HurtsénIlya Zorikhin NilssonEmanuel M DoganKristofer F Nilsson

Published in: Drug design, development and therapy (2020)

Intravenous PDNO was a more potent pulmonary vasodilator than iNO in pulmonary hypertension, with no severe side effects. Hence, this study supports the potential of iv PDNO in the treatment of acute pulmonary hypertension.

Keyphrases

pulmonary hypertension
nitric oxide
pulmonary artery
liver failure
pulmonary arterial hypertension
drug induced
respiratory failure
nitric oxide synthase
aortic dissection
hydrogen peroxide
hepatitis b virus
human health
coronary artery
combination therapy
acute respiratory distress syndrome